Selecting Endocrine Therapy for Breast Cancer

What Role Does HER-2/neu Status Play?

Tatiana M. Prowell, Deborah Kay Armstrong

Research output: Contribution to journalArticle

Abstract

Most women with breast cancer that overexpresses either estrogen (ER+) or progesterone receptors (PR+) will be treated with an endocrine agent. Although ER and PR are the only validated predictive markers of response to hormonal therapy, many women with hormone receptor-positive (HR+) tumors will fail to respond to endocrine treatment or develop hormone resistant disease. Another tumor marker, HER-2/neu, is an oncogene whose amplification or protein overexpression predicts response to a monoclonal antibody targeting HER-2/neu, as well as to anthracycline-based chemotherapy. Preclinical and some clinical data suggest that HER-2/neu positivity may also predict for relative resistance to endocrine therapy. Interpretation of clinical data addressing this issue is confounded by largely retrospective study designs and considerable heterogeneity in patient populations and methods of marker detection and interpretation. At this writing, HER-2/neu expression should not influence the decision to use endocrine therapy.

Original languageEnglish (US)
Pages (from-to)681-687
Number of pages7
JournalSeminars in Oncology
Volume33
Issue number6
DOIs
StatePublished - Dec 2006

Fingerprint

Breast Neoplasms
Hormones
Anthracyclines
Progesterone Receptors
Therapeutics
Tumor Biomarkers
Oncogenes
Estrogen Receptors
Retrospective Studies
Monoclonal Antibodies
Drug Therapy
Population
Neoplasms
Proteins

ASJC Scopus subject areas

  • Oncology

Cite this

Selecting Endocrine Therapy for Breast Cancer : What Role Does HER-2/neu Status Play? / Prowell, Tatiana M.; Armstrong, Deborah Kay.

In: Seminars in Oncology, Vol. 33, No. 6, 12.2006, p. 681-687.

Research output: Contribution to journalArticle

@article{00551435e9cb4fe0b44b359bc99fee2e,
title = "Selecting Endocrine Therapy for Breast Cancer: What Role Does HER-2/neu Status Play?",
abstract = "Most women with breast cancer that overexpresses either estrogen (ER+) or progesterone receptors (PR+) will be treated with an endocrine agent. Although ER and PR are the only validated predictive markers of response to hormonal therapy, many women with hormone receptor-positive (HR+) tumors will fail to respond to endocrine treatment or develop hormone resistant disease. Another tumor marker, HER-2/neu, is an oncogene whose amplification or protein overexpression predicts response to a monoclonal antibody targeting HER-2/neu, as well as to anthracycline-based chemotherapy. Preclinical and some clinical data suggest that HER-2/neu positivity may also predict for relative resistance to endocrine therapy. Interpretation of clinical data addressing this issue is confounded by largely retrospective study designs and considerable heterogeneity in patient populations and methods of marker detection and interpretation. At this writing, HER-2/neu expression should not influence the decision to use endocrine therapy.",
author = "Prowell, {Tatiana M.} and Armstrong, {Deborah Kay}",
year = "2006",
month = "12",
doi = "10.1053/j.seminoncol.2006.08.016",
language = "English (US)",
volume = "33",
pages = "681--687",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Selecting Endocrine Therapy for Breast Cancer

T2 - What Role Does HER-2/neu Status Play?

AU - Prowell, Tatiana M.

AU - Armstrong, Deborah Kay

PY - 2006/12

Y1 - 2006/12

N2 - Most women with breast cancer that overexpresses either estrogen (ER+) or progesterone receptors (PR+) will be treated with an endocrine agent. Although ER and PR are the only validated predictive markers of response to hormonal therapy, many women with hormone receptor-positive (HR+) tumors will fail to respond to endocrine treatment or develop hormone resistant disease. Another tumor marker, HER-2/neu, is an oncogene whose amplification or protein overexpression predicts response to a monoclonal antibody targeting HER-2/neu, as well as to anthracycline-based chemotherapy. Preclinical and some clinical data suggest that HER-2/neu positivity may also predict for relative resistance to endocrine therapy. Interpretation of clinical data addressing this issue is confounded by largely retrospective study designs and considerable heterogeneity in patient populations and methods of marker detection and interpretation. At this writing, HER-2/neu expression should not influence the decision to use endocrine therapy.

AB - Most women with breast cancer that overexpresses either estrogen (ER+) or progesterone receptors (PR+) will be treated with an endocrine agent. Although ER and PR are the only validated predictive markers of response to hormonal therapy, many women with hormone receptor-positive (HR+) tumors will fail to respond to endocrine treatment or develop hormone resistant disease. Another tumor marker, HER-2/neu, is an oncogene whose amplification or protein overexpression predicts response to a monoclonal antibody targeting HER-2/neu, as well as to anthracycline-based chemotherapy. Preclinical and some clinical data suggest that HER-2/neu positivity may also predict for relative resistance to endocrine therapy. Interpretation of clinical data addressing this issue is confounded by largely retrospective study designs and considerable heterogeneity in patient populations and methods of marker detection and interpretation. At this writing, HER-2/neu expression should not influence the decision to use endocrine therapy.

UR - http://www.scopus.com/inward/record.url?scp=37249092437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249092437&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2006.08.016

DO - 10.1053/j.seminoncol.2006.08.016

M3 - Article

VL - 33

SP - 681

EP - 687

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6

ER -